5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$9M | — | — | -$7M | — | $13M |
| 2024 | $780000 | -$6M | 0.3% | -573.8% | -$6M | — | $2M |
| 2023 | $1M | -$8M | 24.4% | -701.1% | -$9M | — | $3M |
| 2022 | $2M | -$10M | 16.3% | -548.8% | -$9M | — | $4M |
| 2021 | $1M | -$8M | -3.0% | -448.1% | — | — | $13M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$6M | — | — | -$5M | — | $7M |
| Dec '25 | — | -$3M | — | — | -$2M | — | $13M |
| Sep '25 | $146000 | -$3M | -99.3% | -1700.7% | -$2M | — | $3M |
| Jun '25 | — | -$2M | — | — | — | — | $1M |
| Mar '25 | — | -$2M | — | — | -$889000 | — | $669000 |
| Dec '24 | — | -$1M | — | — | -$1M | — | $2M |
| Sep '24 | $126000 | -$1M | 34.9% | -1135.7% | — | — | $2M |
| Jun '24 | — | -$1M | — | — | — | — | $4M |
| Mar '24 | — | -$1M | — | — | — | — | $2M |
| Dec '23 | — | -$2M | — | — | -$2M | — | $3M |
| Sep '23 | — | -$2M | — | — | -$2M | — | $5M |
| Jun '23 | — | -$2M | — | — | -$2M | — | $3M |
| Mar '23 | — | -$2M | — | — | -$3M | — | $5M |
| Dec '22 | — | -$2M | — | — | -$2M | — | $4M |
| Sep '22 | — | -$3M | — | — | -$3M | — | $6M |
| Jun '22 | — | -$3M | — | — | -$2M | — | $9M |
| Mar '22 | — | -$2M | — | — | -$2M | — | $11M |
| Dec '21 | — | -$4M | — | — | — | — | $13M |
| Sep '21 | — | -$2M | — | — | — | — | — |
| Jun '21 | — | -$1M | — | — | — | — | — |
Over the past 4 years, Valion Bio, Inc.'s revenue has declined 14.7% per year. These are computed facts, not advice.
As of FY2025, Valion Bio, Inc. reported — of total debt against $13M of cash; operating income covered interest expense -54.1×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.